HER2 negative, BRCA germline mutated breast cancer MedDRA version: 14.1 Level: PT Classification code 10006187 Term: Breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Conditions
Interventions
Product Name: Niraparib
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Niraparib
CAS Number: 1038915-60-4
Current Sponsor code: L-001946812-005R, L-001946812 and MK-4827
Other descriptive nam
Sponsors
TESARO UK Limited, (c/o Sisec Limited)
TESARO Inc
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histologically or cytologically confirmed HER2-negative metastatic or locally advanced breast cancer that is not amenable to resection or radiation with curative intent. 2. Female and male patients age at least 18 years. 3. Germline BRCA1 or BRCA2 mutation that is considered deleterious or suspected deleterious (include those mutations or translocations termed “deleterious” or “suspected deleterious” according to Myriad reporting) by analysis at a reference laboratory (Myriad Genetic Laboratories, Salt Lake City, UT, USA, or Myriad GmbH, Martinsried, Germany). 4. Measurable disease by RECIST v1.1 or non- measurable disease that is clinically evaluable (except sclerotic-only bone disease; bone-only disease that has a lytic component is allowed). 5. Patients must not have symptomatic uncontrolled brain metastases To be considered controlled, central nervous system (CNS) disease must have undergone treatment (whole brain radiation, radiosurgery or equivalent) at least 1 month previously and the patient has no new or progressive signs or symptoms related to the CNS disease, and are off steroid therapy two weeks. 6. Up to 2 prior cytotoxic regimens for advanced or metastatic breast cancer (not including adjuvant or neo-adjuvant therapy); patients with no prior cytotoxic regimens for advanced or metastatic disease will only be allowed if they relapsed during or within 12 months of (neo-) adjuvant cytotoxic therapy. 7. Prior therapy should have included an anthracycline and a taxane (unless contraindication to those) in the neoadjuvant, adjuvant, or advanced/metastatic setting. a. Hormone receptor positive patients must also have hormone resistant disease; either relapsed while on adjuvant endocrine treatment or wihtin one year of completing adjuvant endocrine treatment, or progression on at least on line of endocrine treatment for advanced cancer. 8. Patients must not have received anticancer chemotherapy, radiotherapy, hormonal therapy, biological therapy, or any other investigational therapy within 3 weeks prior to the start of study treatment. Patients with persistent toxicity (except alopecia) > grade 1 from prior cancer therapy will also be excluded. Bisphosphonate and denosumab are allowed. 9. No prior treatment with a known or putative PARP inhibitor (except iniparib). No other anticancer agent (chemotherapy, hormonal therapy, or other agent) is to be permitted during the course of the study for any patient. 10. Patients must not be platinum resistant defined as: progression of cancer during or within 6 months of completion of prior platinum treatment. 11. ECOG performance status 0-2 (Appendix G). 12. Adequate organ function (assessed within 72 hours prior to the first dose): a. Absolute neutrophil count (ANC) = 1,500 cells/µL b. Platelets = 100,000 cells/µL c. Hemoglobin = 9 g/dL d. Serum creatinine = 1.5 × upper limit of normal (ULN) or = 50 mL/min using Cockcroft-Gault equation e. Total bilirubin = 1.5 × ULN OR direct bilirubin = ULN f. Aspartate transaminase (AST) and alanine transaminase (ALT) = 2.5 × ULN or < 5 × ULN with liver metastases 13. Patients able to swallow and retain oral tablets 14. Female patients must not be pregnant or breast feeding a. Female patient of childbearing potential must have a negative serum pregnancy test. 15. Patients of child bearing potential who are sexually active and their partners must agree to the use of a highly effective form of contraception throughout their participation during the st
Exclusion criteria
Exclusion criteria: No exclusion criteria are defined per protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective of this study is to compare progression-free survival (PFS), as assessed by blinded central review, of patients with advanced/metastatic HER2-negative gBRCAmut breast cancer when treated with niraparib as compared to those treated with physician’s choice single agent chemotherapy standards (eribulin, vinorelbine, gemcitabine or capecitabine).;Secondary Objective: To compare overall survival of patients with advanced/metastatic HER2-negative gBRCAmut breast cancer when treated with niraparib as compared to those treated with physician's choice single agent chemotherapy standards. - Establish germline BRCA mutation status of screened patients using a centrally provided, validated test. Additional tests will be performed to determine concordance between tests for the purpose of developing a commercial diagnostic test. - To evaluate safety and tolerability as measured in all AEs - To compare PFS using investigator assessment of progression - To evaluate time to treatment failure - To compare response rate and duration of response - To compare time to deterioration of health-related quality of life - To describe subsequent therapies and potential relationships with outcomes - To assess genectic and non-genetic biomarkers relating to treatment efficacy For a detailed listing and for objectives 9 to 10 please refer to the Protocol.;Primary end point(s): Progression free survival per central review;Timepoint(s) of evaluation of this end point: Per Protocol | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): 1. Overall survival (key secondary efficacy endpoint). 2. Determine concordance between gBRCAmut tests for the purpose of developing a commercial companion diagnostic test. 3. Safety and tolerability, as documented by AEs and laboratory values 4. PFS using investigator assessment of progression 5. Time to treatment failure 6. Response rate and duration of response 7. Health-related quality of life: QLQ-C30 and EQ5D-5L (see chapter 10). 8. Subsequent therapies and potential relationships with outcomes 9. To assess outcomes by germline mutation BRCA1 vs BRCA2;Timepoint(s) of evaluation of this end point: Per Protocol | — |
Countries
Belgium, France, Greece, Hungary, Iceland, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom
Contacts
Public ContactMartin Huber
TESARO Inc.
Outcome results
None listed